Danish pharma giant focused on diabetes, obesity therapies and related devices
Investors are weighing mixed signals from CNBC and The Guardian pieces, with discussions centering on stock picks and consumer sentiment as markets digest new information. The tone remains cautious as investors assess potential moves in tech and consumer names amid evolving macro cues.
A new weight‑loss pill version of semaglutide has launched in the UK for private prescriptions, offering an alternative to injections. The tablet requires strict dosing and a fasting routine and is not yet NHS‑funded. Several outlets warn about counterfeit pills as access broadens.
Vivani Medical is developing a long-acting semaglutide implant to deliver GLP-1 therapy over months, potentially replacing injections. Novo Nordisk is evaluating the device to improve adherence and reduce weight regain, but regulatory and cost questions remain as trials proceed.
Novo Nordisk has filed a US lawsuit accusing Eli Lilly of false advertising over weight‑loss and diabetes drugs, arguing Lilly used outdated trial data to claim superiority. Lilly defends its campaigns, citing SURMOUNT‑5 results. The case centers on GLP-1 treatments and the race for market dominance, with potential damages and corrective advertising at stake.
The White House has proposed phased tariffs on imported generic medicines, arguing for a U.S.-based manufacturing boost. The plan starts with two years of zero tariffs, followed by 100% and then 200% levies, to spur domestic production. Industry groups warn the move could raise prices for patients while onshoring efforts face structural hurdles. Major manufacturers say margins are thin and shifting production could take years.
Regulators are reviewing a BMJ study linking GLP-1 receptor agonists to a higher risk of alopecia. The study compares hair-loss rates in GLP-1 users against SGLT-2 and DPP-4 inhibitors, with findings suggesting a 37% higher risk versus SGLT-2 and 68% higher versus DPP-4. Hair loss appears non-scarring and potentially reversible, often tied to weight loss and nutritional factors.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
Lilly and Novo Nordisk have surpassed forecasts in Q2, widening the gap in the obesity-drug space. Lilly leads in the US with about 61% share; Novo raises full-year outlook but faces questions about Wegovy's growth and its pipeline. Investors are watching whether Novo can sustain momentum as competition intensifies.
Eli Lilly has posted another quarter of strong results driven by Mounjaro and Zepbound, lifting full-year guidance. Novo Nordisk trails in growth momentum as it works to regain share and assure investors of a clear long-term path. Foundayo’s launch adds a new dimension to Lilly’s portfolio.
President Trump has signed an executive order directing federal health officials to cut the federal recommended childhood vaccine list, to split the combined MMR vaccine into separate measles, mumps and rubella doses once single‑disease products are available, and to space routine immunisations across separate medical visits. Public health groups and drugmakers have said the changes lack scientific support and will increase missed vaccinations during a major U.S. measles outbreak.
Harvey Nichols has been put up for sale and is undergoing a turnaround led by Frasers Group. The six-storefront estate, including Edinburgh’s flagship, will continue operating while a broader restructuring is pursued, with potential integration of Flannels and the wider Frasers luxury ecosystem.
This week has seen several medical research and regulatory developments. Insilico Medicine has reported that its experimental drug rentosertib changed blood‑protein patterns that aging clocks read as three to four years younger in a small trial. Stanford teams have published studies showing they can grow hindbrain neurons separately and implant human cortical organoids into mice. The US health department has appointed permanent directors for three FDA centers.
Anthropic has built a wet lab in the San Francisco Bay Area to accelerate biology work, confirming a shift from in silico research to real-lab experimentation. The move comes amid warnings about AI risks and a looming IPO, with leadership stressing safety while pursuing faster drug development.
Lilly has reported growth in the oral GLP-1 pill market and expansion plans, with one-third of new oral-GLP-1 patients on Foundayo. The company is also building a new manufacturing facility in Houston and reiterating its commitment to meeting rising demand as Medicare coverage broadens access to obesity drugs.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
New lawsuits claim GLP-1 diabetes drugs may cause nonarteritic anterior ischemic optic neuropathy (NAION), a rare but serious eye condition. Regulators are reviewing evidence, while manufacturers dispute the claims. Reports cite studies showing mixed results on risk, with the absolute risk remaining very low.
Anthropic says its Claude model autonomously identified a CRISPR-like enzyme system while scanning vast DNA data in its new San Francisco biology lab; experts urge caution and note findings require peer review and verification.
Anthropic has expanded Claude Startup to include more startups, offering up to $45,000 in credits, a $1,000 API credit, and a free year of Claude Team for up to five seats. The initiative, announced during SF Tech Week, aims to accelerate enterprise adoption of Claude and strengthen ties with early-stage companies.